Posted by Tomatheus on May 11, 2010, at 20:11:41
In reply to Curious about Moclobemide, posted by bearfan on May 11, 2010, at 14:08:12
Bearfan,
The following quotes are from a meta-analysis that was conducted by doctors Francisco Lotufo-Neto, Madhukar Trivedi, and Michael E. Thase in the late 90s.
Please note that MOC=moclobemide, and AT=atypical.
"MOC, which is available throughout much of the world (but not the United States), is significantly more effective than placebo and, at the least, comparable to the SSRIs in both efficacy and tolerability."
"Across inpatient and outpatient settings, eight studies compared MOC with SSRIs. There were two contrasts with fluvoxamine and six against fluoxetine ... In these eight trials, MOC had an ITT response rate of 58.0% (3.4%). In the AT samples, the MOC response rate was 67.9% (3.8%). The difference between MOC and the SSRIs was 6.4% (3.9 %) in the ITT analysis, and, for the AT sample, the difference was of 4.8% (4.1%). In both cases, there was a small but reliable advantage favoring MOC over the SSRIs. However, the clinical significance of these such small differences in response rates is certainly debatable."
Tomatheus
==
REFERENCE
Lotufo-Neto, F., Trivedi, M., & Thase, M.E. (1999). Meta-analysis of the reversible inhibitors of monoamine oxidase type a moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology, 20, 226-247. Abstract: http://www.ncbi.nlm.nih.gov/pubmed/10063483
poster:Tomatheus
thread:947110
URL: http://www.dr-bob.org/babble/20100504/msgs/947156.html